(VIANEWS) – CTT CORREIOS PORT (CTT.LS), HAFNIA LIMITED (HAFNI.OL), NAVAMEDIC (NAVA.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. CTT CORREIOS PORT (CTT.LS)
327.5% sales growth and 22.58% return on equity
CTT – Correios De Portugal, S.A., together with its subsidiaries, provides postal and financial services worldwide. It operates through Mail, Express & Parcels, Financial Services & Retail, and Bank segments. The company offers courier and urgent mail transport services; postal financial services; and banking services. It also engages in the business of payments related to collection of invoices and fines. In addition, the company enables the payment of various services and utilities through a network of approximately 5,000 agents covering business outlets as stationery stores, tobacco shops, kiosks, and supermarkets. It operates a retail network of 566 post offices; 1,808 postal agencies; 223 postal delivery offices; 4,576 postal delivery routes; and a fleet of 3,925 vehicles. The company was formerly known as Correio Publico. CTT – Correios De Portugal, S.A. was founded in 1520 and is headquartered in Lisbon, Portugal.
Earnings Per Share
As for profitability, CTT CORREIOS PORT has a trailing twelve months EPS of €0.11.
PE Ratio
CTT CORREIOS PORT has a trailing twelve months price to earnings ratio of 32.18. Meaning, the purchaser of the share is investing €32.18 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.58%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.1%, now sitting on 893.88M for the twelve trailing months.
More news about CTT CORREIOS PORT.
2. HAFNIA LIMITED (HAFNI.OL)
155.2% sales growth and 48.16% return on equity
Hafnia Limited owns and operates oil product tankers. The company operates through four segments: Long Range II (LR2), Long Range I (LR1), Medium Range (MR), and Handy size (Handy). It transports petroleum oil products, vegetable oil, and easy chemicals to national and international oil companies, and chemical companies, as well as trading and utility companies. The company provides ship owning, ship-management, chartering, investment, and agency office services. As of March 29, 2022, it operated a fleet of 237 vessels, including newbuilds, of which 145 are owned or chartered-in, including 10 owned LR2s, 40 owned and chartered-in LR1s, 58 owned and chartered-in MRs, and 29 owned Handy and eight stainless steel 25K vessels. The company is based in Hamilton, Bermuda. Hafnia Limited is a subsidiary of BW Group Limited.
Earnings Per Share
As for profitability, HAFNIA LIMITED has a trailing twelve months EPS of kr3.38.
PE Ratio
HAFNIA LIMITED has a trailing twelve months price to earnings ratio of 17.1. Meaning, the purchaser of the share is investing kr17.1 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 48.16%.
More news about HAFNIA LIMITED.
3. NAVAMEDIC (NAVA.OL)
72.2% sales growth and 16.31% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, women's health, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr0.45.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 88.22. Meaning, the purchaser of the share is investing kr88.22 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.31%.
Volume
Today’s last reported volume for NAVAMEDIC is 19719 which is 18.54% below its average volume of 24207.
Moving Average
NAVAMEDIC’s value is way higher than its 50-day moving average of kr36.02 and way above its 200-day moving average of kr32.99.
Sales Growth
NAVAMEDIC’s sales growth is 25.1% for the ongoing quarter and 72.2% for the next.
More news about NAVAMEDIC.
4. MELEXIS (MELE.BR)
18.6% sales growth and 45.26% return on equity
Melexis NV designs, develops, tests, and markets advanced integrated semiconductor devices primarily for the automotive industry in Europe, the Middle-East, Africa, the Asia Pacific, and North and Latin America. The company provides magnetic position, latch and switch, current, inductive position, tire monitoring, temperature, optical, pressure, and speed sensor ICs. It also offers embedded motor driver, fan and pump, LED, and pre driver ICs; and LIN/CAN system basis, NFC/RFID, radio-frequency receiver and transmitter, and switch controller ICs. The company was founded in 1988 and is headquartered in Ieper, Belgium. Melexis NV is a subsidiary of Xtrion N.V.
Earnings Per Share
As for profitability, MELEXIS has a trailing twelve months EPS of €1.89.
PE Ratio
MELEXIS has a trailing twelve months price to earnings ratio of 53.8. Meaning, the purchaser of the share is investing €53.8 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 45.26%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 34.7%, now sitting on 836.16M for the twelve trailing months.
More news about MELEXIS.
